Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
tolinapant (ASTX660)
i
Other names:
ASTX660, ASTX 660, ASTX-660, 1799328-86-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Otsuka
Drug class:
XIAP antagonist, cIAP1 antagonist, cIAP2 antagonist
Related drugs:
‹
idronoxil (0)
NV06 (0)
idronoxil (0)
NV06 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Suspended
Phase 1
National Cancer Institute (NCI)
Suspended
Last update posted :
02/06/2025
Initiation :
08/04/2025
Primary completion :
05/17/2027
Completion :
05/17/2027
RIPK1
|
Halaven (eribulin mesylate) • tolinapant (ASTX660)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login